Blog
RSS FeedPosted by Michael Wonder on 26 Sep 2018
The health industry as an economic priority for Victoria, joint statement
26 September 2018 - Victoria has world-leading competitive advantages in the health industry, which encompasses health and medical research, biotechnology, ...
Posted by Michael Wonder on 17 Sep 2018
Antimicrobial resistance: FDA discusses reimbursement reforms
17 September 2018 - Reimbursement reforms for antimicrobial treatments could include “a mix of milestone payments and subscription fees for ...
Posted by Michael Wonder on 30 Aug 2018
FDA’s comprehensive effort to advance new innovations: initiatives to modernise for innovation
29 August 2018 - Our longstanding goal for medical care is to ensure that the right drug or device is delivered ...
Posted by Michael Wonder on 29 Aug 2018
FDA launches new pilot to advance innovative clinical trial designs as part of agency’s broader program to modernise drug development and promote innovation in drugs targeted to unmet needs
29 August 2018 - Today, the U.S. FDA announced a new pilot program (“Complex Innovative Designs Pilot Meeting Program”) in which ...
Posted by Michael Wonder on 29 Aug 2018
Developing tools to support digital health and medtech innovation
8 August 2018 - NICE is involved in two key initiatives with national partners to achieve these aims by developing standards ...
Posted by Michael Wonder on 16 Aug 2018
Statement from FDA Commissioner on advancing the science and regulation of live microbiome-based products used to prevent, treat, or cure diseases in humans
16 August 2018 - Over the last several years, there’s been growing scientific and public interest in the role of microorganisms ...
Posted by Michael Wonder on 01 Aug 2018
FDA supports critical research to spur innovation for continuous manufacturing technology to support and advance drug and biologics development
1 August 2018 - We know that novel manufacturing technologies for both small-molecule drugs and biological products have great potential to ...
Posted by Michael Wonder on 12 Jul 2018
After feuding with drug middlemen, startup fields a competitor
12 July 2018 - Blue Eagle Health manages a 33,000 pharmacy network for Blink. ...
Posted by Michael Wonder on 11 Jul 2018
Defining innovation with respect to new medicines: a systematic review from a payer perspective
11 July 2018 - The aim of this study was to investigate how innovation is defined with respect to new ...
Posted by Michael Wonder on 06 Jun 2018
Big pharma wants to invest more in Australian biotech says Greg Hunt
6 June 2018 - Big pharma is "looking at Australia as the next destination in the developed world, the emerging first-world ...
Posted by Michael Wonder on 06 Jun 2018
FDA’s new efforts to advance biotechnology innovation
6 June 2018 - Scientific advances in biotechnology, such as genome editing and synthetic biology, hold enormous potential to improve human ...
Posted by Michael Wonder on 05 Jun 2018
Embracing competition to empower biosimilars
5 June 2018 - In 2017, there were 46 new novel drug innovations, including new treatments for cancers, Parkinson’s disease, ...
Posted by Michael Wonder on 30 May 2018
As part of efforts to combat opioid crisis, FDA launches innovation challenge to spur development of medical devices ‒ including digital health and diagnostics ‒ that target pain, addiction and diversion
30 May 2018 - Agency will work closely with selected applicants to accelerate product development. ...
Posted by Michael Wonder on 28 May 2018
Health insurer HCF looks to start-ups, innovation to help retain members
28 May 2018 - Australia's third largest health insurer HCF is betting on its start-up accelerator Catalyst to help it ...
Posted by Michael Wonder on 11 Apr 2018
Breakthrough-therapy designation — an FDA perspective
12 April 2018 - Recent medical advances, such as targeted therapies for specific tumour genomic defects, checkpoint inhibitors for cancers, and ...